Clinical Expert Submission Template
|
|
- Paul Watson
- 6 years ago
- Views:
Transcription
1 Clinical Expert Submission Template Thank you for agreeing to give us a personal statement on your view of the technology and the way it should be used in the NHS. Health care professionals can provide a unique perspective of the technology within the context of current clinical practice which is not typically available from the published literature. To assist you in making your statement we have provided a template. The questions are intended as prompts to guide you. It is not essential that you answer all of them. Your statement can be as brief as you like. We suggest a maximum limit of 8 pages. If there are special circumstances for exceeding this limit please attach an Executive Summary. What is the place of the technology in current practice? We would like to know how the condition is currently treated in the NHS. Is there significant geographical variation in current practice? Are there differences in opinion between professionals as to what current practice should be? What are the current alternatives to the technology and what are their respective advantages and disadvantages? Are there any subgroups of patients with the condition who have a different prognosis from the typical patient? Are there differences in the capacity of different subgroups to benefit from or to be put at risk by the technology? In what setting should/could the technology be used for example, primary or secondary care, specialist clinics? Would there be any requirements for additional professional input (for example, community care, specialist nursing, other healthcare professionals)? If the technology is already available, is there variation in how it is being used in the NHS? Is it always used within its licensed indications? If not, under what circumstances does this occur? Please tell us about any relevant clinical guidelines and comment on the appropriateness of the methodology used in developing the guideline and the specific evidence that underpinned the various recommendations. Adjuvant treatment for breast cancer current practise Invasive primary breast cancer (ie breast cancer which is macroscopically confined to breast and regional lymph nodes) is ordinarily treated by excision of the tumour, followed by a course of adjuvant chemotherapy (if appropriate), breast radiotherapy (following breast-conserving surgery and to chest wall for higher risk patients following mastectomy) and by 5 years of endocrine therapy if the tumour is steroid hormone receptor positive. There is no identifiable subgroup of patients that does not potentially benefit from chemotherapy. Adjuvant chemotherapy confers a fixed relative risk reduction within the constraints of the parameters discussed below. Patients with a higher risk of breast cancer death will therefore experience a greater absolute risk reduction than those with a lower risk. There are 4 main factors that determine the likely chance that chemotherapy will benefit an individual. 1. Risk associated with disease: risk is defined by the conventional pathological parameters of nodal involvement, grade and tumour size, modified by secondary parameters including receptor expression and vascular invasion. Patients at highest risk by virtue of histological characteristics of their tumour will benefit most from chemotherapy. 2. The benefits of chemotherapy decline with increasing age. It is generally accepted that chemotherapy should be offered to all women under 35 to 40 whilst there is insufficient evidence to justify routine treatment of the over 70 s. 3. Chemotherapy is relatively less effective for women with steroid hormone receptor positive disease over the age of 50. The situation in younger women is less clear cut because chemotherapy-induced ovarian failure interacts with the chemotherapy effect unlike tamoxifen (or aromatase inhibitors). The 2000 Oxford Overview (Lancet 2005, 365: ) suggests that steroid hormone receptor status is unimportant but several recent trials using chemotherapy not particularly likely to cause ovarian failure suggest an attenuated effect in hormone receptor positive disease. 4. The choice of chemotherapy regimen will affect benefit. Historically 6 months of the CMF combination (cyclophosphamide, methotrexate & fluorouracil administered twice during a 28-day cycle) or 3 months of AC (doxorubicin & cyclophosphamide given once every 3 weeks for 4 cycles ie ACx4) were used. These two regimens, which have been shown to be equivalent in two large randomised clinical trials have been largely superseded by more effective combinations in the NHS and indeed globally (see below). There are no generally accepted national guidelines for selecting which patients should be offered adjuvant chemotherapy. However there is a broad consensus amongst oncologists, reflected in local guidelines, that for patients without major co-morbidities, the threshold for offering adjuvant chemotherapy should be an estimated reduction in the risk of death at 10 years of 3-5%. This would include all patients with involved axillary lymph nodes under the age of 70 and patients with significant risk factors who do not have nodal disease. Many oncologists use a computerised tool to refine risk and benefit estimates. The best known of these is Adjuvant! ( which has been validated in a community setting (Olviotto, J Clin Oncol 2005, 23: ). 1
2 The most widely used adjuvant chemotherapy regimens current in the NHS are the anthracycline-based FEC (fluorouracil, epirubicin & cyclophosphamide given once every 3 weeks for 6 cycles) and E-CMF (epirubicin given once every 3 weeks for 4 cycles, followed by 4 monthly cycles of the CMF combination, a block sequential regimen). E-CMF has been shown to be approximately 40% superior to 6 months of CMF in the NEAT trial. Whilst there are no individual trials that show FEC as used in the UK to be superior to CMF or ACx4, the 2000 Oxford Overview suggests that FEC is some 25% better than CMF. No formal efficacy comparison has been performed between the two regimens but the TACT trial may provide some information when the initial analysis is performed, probably in late There are uncertainties as to the optimal epirubicin dose to be used in the FEC combination most Networks have recently escalated from the 60mg/m 2 used in TACT to 75mg/m 2 but there is only weak evidence to support this dose, rather than the mg/m 2 used in much of Europe. Nevertheless FEC is a simpler and shorter regimen than E-CMF (6 vs 12 injections) and as it uses fewer resources, is preferred by patients and is not obviously inferior to E-CMF, it is the regimen of choice in about 60% of NHS units. There is general agreement amongst oncologists that when adjuvant chemotherapy is given, it should be the first treatment following surgery. Radiotherapy treatment is not commenced until chemotherapy is completed because of the unpredictable interaction between some cytotoxics, particularly anthracyclines, and radiation. Similarly endocrine therapy is not given concurrently with chemotherapy because of concerns about a possible increased incidence of venous thromboembolism and because of recent data from a randomised controlled trial that suggests that concomitant tamoxifen decreases the efficacy of chemotherapy. Primary chemotherapy current practise The use of primary chemotherapy ie initial treatment of primary breast cancer with chemotherapy, followed by surgery is variable in the NHS. The generally accepted indications are to make locally advanced inoperable tumours operable and to down-stage larger tumours to permit breast-conserving surgery. The second indication is very much dependent on the attitudes that prevail in individual MDT s. Until recently, the most commonly used chemotherapy regimens used for primary chemotherapy has been 6 cycles of AC or EC (epirubicin & cyclophosphamide). Many Networks have now revised their guidelines to suggest that if there is an incomplete tumour response after 4 cycles of AC/EC then chemotherapy should be switched to docetaxel. This has been informed by the NSABP B27 trial (Bear, J Clin Oncol : ), which showed that 4 cycles of AC followed by 4 cycles of docetaxel increased clinical and pathological response rates by 50% in comparison to ACx4 alone, by UK clinician experience with the Anglo-Celtic II trial and by data from the NSABP B17 primary chemotherapy trial that shows that pathological complete response is associated with improved survival. The current NCRN-approved Neo-tAnGo trial incorporates a randomised comparison between paclitaxel and paclitaxel-gemcitabine. Treatment setting All chemotherapy, including chemotherapy for breast cancer should be supervised by a trained oncologist or consultant nurse and be administered by suitably trained staff as specified by the Manual for Cancer Standards. Current use of Docetaxel Adjuvant docetaxel is little used in the NHS (in contrast to North America), because of funding issues. There is however a strong groundswell of opinion amongst NHS oncologists that it should be used for higher risk patients. Some Networks are now incorporating adjuvant docetaxel for high risk younger patients into their guidelines and are applying for funding of adjuvant docetaxel therapy in high-risk patients on a cost-per-case basis. The great majority of adjuvant docetaxel used for NHS patients is administered using block-sequential regimens such as FECx4 followed by docetaxelx4 which are used in preference to combination regimens such as TAC (docetaxel, doxorubicin & cyclophosphamide) although the only licensed indication for adjuvant docetaxel is in the context of the TAC regimen. The reasons for this preference include the greater cost of the TAC regimen (which cannot be administered without haematological growth factor, ie G-CSF support), familiarity with block-sequential regimens from participation in the UK TACT study and in the primary chemotherapy setting, and the general move away from doxorubicin amongst UK breast oncologists because of concern about cardiac toxicity. The use of adjuvant docetaxel in privately funded patients is more widespread but the regimens in use seem to be similar to those used in NHS practise. Docetaxel is widely used for off-study primary chemotherapy for breast cancer (see above). There is a strong desire to incorporate trastuzumab into docetaxel-containing primary chemotherapy regimens following the small but highly positive study conducted at the MD Anderson Cancer Center (Buzdar, J Clin Oncol : ). Docetaxel is widely used to treat advanced breast cancer (and is NICE approved for this purpose). The majority of taxane treatment of advanced disease is with docetaxel monotherapy rather than with paclitaxel or with the docetaxel-capecitabine combination. Docetaxel-capecitabine has been recommended by NICE but is widely considered to be associated with unacceptable toxicity. The preference for docetaxel over paclitaxel is informed by the results of a randomised comparison between the two drugs, administered at licensed doses in the metastatic setting (Jones, J Clin Oncol 2005: 23: ), which showed a greater overall survival for patients treated with docetaxel. Guidelines There are no accepted guidelines for adjuvant use of docetaxel apart from local Network guidelines, as discussed above. NICE has issued guidance on docetaxel in the metastatic setting. The Scottish Medicines Consortium has approved the TAC regimen (docetaxel, doxorubicin & cyclophosphamide) for adjuvant use. 2
3 The advantages and disadvantages of the technology NICE is particularly interested in your views on how the technology, if available, compares with current alternatives used in the UK. Is the technology easier of more difficult to use and are there any practical implications (for example, concomitant treatments, other additional clinical requirements, patient acceptability/ease of use or the need for additional tests) surrounding its use? If appropriate, please give your view on the nature of any rules, informal or formal, for starting and stopping the use of the technology; this might include the requirement for additional testing to identify appropriate subgroups for treatment or to assess response and the potential for discontinuation. If you are familiar with the evidence base for the technology, please comment on whether the use of the technology in clinical practice reflects that observed under clinical trial conditions. Do the circumstances in which the trials were conducted reflect current UK practice, and if not, how could the results be extrapolated to a UK setting? What, in your view, are the most important outcomes and were they measured in the trials? If surrogate measures of outcome were used, do they adequately predict long-term outcomes? What is the relative significance of any side effects or adverse reactions? In what ways do these have an impact on the management of the condition and the patient s quality of life? Are there any adverse effects that were not apparent in the clinical trials but have come to light subsequently during routine clinical practice? Comment on the adjuvant docetaxel trials and current UK adjuvant chemotherapy practise Two trials have clearly demonstrated the superiority of docetaxel-containing adjuvant chemotherapy over regimens similar to those in current use in the NHS. BCIRG 001 (Martin, New Engl J Med : ), which was conducted in women with node-positive breast cancer showed an approximately 30% improvement in both relapse-free survival and overall survival in women treated with 6 3-weekly cycles of TAC (docetaxel, doxorubicin & cyclophosphamide) compared to 6 cycles of FAC (fluorouracil, doxorubicin & cyclophosphamide). The result is highly significant and since the FAC regimen used in this study closely resembles current chemotherapy in use in the NHS (FAC and FEC seem to be equivalent according to the 2000 Oxford Overview), this study is clearly relevant. Significant haematological toxicity was associated with this regimen (discussed below) and there is a preference by many UK oncologists for the blocksequential regimens such as those used in PACS 01 and NSABP B27. PACS 01 (presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2004 but not yet formally published) was also conducted in women with node-positive primary breast cancer. The randomisation was between 6 cycles of FEC (with an epirubicin dose of 100mg/m 2 ) given every 3 weeks and 3 cycles of FEC followed by 3 cycles of docetaxel every weeks. In this study, there was a 17% reduction in risk of recurrence and a 23% reduction in risk of death. It is noteworthy that haematological toxicity was greater in the control arm of this study. The trial design is broadly similar to the as yet unanalysed UK TACT study, which used a experimental arm of 4 cycles of FEC (epirubicin dose 60mg/m 2 ) followed by 4 cycles of docetaxel. Nearly 4200 patients were randomised to TACT and the majority of UK oncologists treating breast cancer participated. Although epirubicin doses used in FEC have been increased in many Networks since the completion of TACT in 2002, there is still reluctance by the majority to use the 100mg/m 2 dose used in the PACS study. When adjuvant taxanes are used in the UK in block-sequential regimes, in the majority of cases, the regimen used is FEC x4 (with epirubicin 60mg/m 2 or 75mg/m 2 ) followed by docetaxel x4. The incorporation of taxanes into neoadjuvant chemotherapy (discussed in the previous section) is informed by the block-sequential regimens used in the NSABP B27 trial, which used a very similar regimen. It is always difficult to make between trial and regimen comparisons, but FEC with the higher dose of epirubicin used in the PACS study has previously been shown to superior to FEC with 50mg/m 2 epirubicin) in the FACS 05 study (J Clin Oncol 2001, 19:602-11). Many of the FEC studies that were included in the 2000 Oxford Overview used lower doses of epirubicin, so it seems likely that FEC with 100mg/m 2 epirubicin (FEC100) is superior to FAC (and to FEC60). The apparent difference between docetaxel benefit in the BCIRG and PACS trials may therefore be the consequence of difference in the control arms rather than in the experimental regimens. The positive result from the PACS study confirms that docetaxel really does confer a significant added benefit to an optimal anthracycline regimen. The US Oncology study 9735 (Jones, Proc ASCO 2003 abstr 59, updated at SABCS 2005) has demonstrated a 33% improvement in disease-free survival for patients treated with 4 cycles of doxorubicin-docetaxel in comparison to 4 cycles of AC. The similar ECOG E2197 (Goldstein, Proc ASCO 2005 abstr 512) however has failed to demonstrate a significant advantage for doxorubicin-docetaxel. As the control arm used in both studies is considered inferior to FEC or E-CMF used in current NHS practise, it is difficult to see their relevance. All of these trials have used disease-free survival as their primary endpoint. This is usually a composite endpoint incorporating local recurrence (which is treatable but is associated with increased future mortality), distant recurrence (which is inevitably fatal, although on average not for 2-3 years) and death. The most relevant endpoint to clinical practise is overall survival although it must be emphasised that the experience of local recurrence is deeply distressing to the vast majority of affected women. Experience from the vast majority of historical trials of adjuvant for chemotherapy is that improvements in disease-free survival are in the fullness of time translated into improvements in overall survival. Disease-free survival is therefore an acceptable surrogate endpoint for overall survival, especially as due to the prolonged natural history of breast cancer, there can often be an interval of several years between the emergence of DFS and OS benefits. 3
4 Docetaxel toxicity Docetaxel, in contrast to current anthracycline chemotherapy regimens is neurotoxic. A significant minority of women develop a sensory peripheral neuropathy during treatment which may take many months to resolve. The long-term outcome of taxane neuropathy has in my view been inadequately studied. This is clearly relevant to a patient population that will hopefully survive for many years and in which the number needed to treat for benefits to accrue may be significant. All oncologists who prescribe taxanes are familiar with this toxicity and with modifying chemotherapy to minimise it. In the BCIRG 001 study, the incidence of severe (grade 3-4) toxicities in patients treated with TAC (docetaxel, doxorubicin & cyclophosphamide) was 36% compared to those treated with 27% FAC (fluorouracil, doxorubicin & cyclophosphamide). Most of the difference is due to the increased incidence of haematological toxicities with TAC, with 25% of patients experiencing febrile neutropenia rate compared to 2.5% with FAC. Although the majority of these episodes were not severe and there were no consequent deaths, febrile neutropenia in the NHS is ordinarily managed by emergency admission for intravenous antibiotics. Such admissions typically last for 3-5 days, sometimes longer. The risk of febrile neutropenia can be minimised by dose reduction, which is undesirable because a potential reduction in treatment efficacy or by the administration of prophylactic G-CSF. G-CSF exists in 2 formulations. The standard form is given by daily subcutaneous injection (typically day 4-11), whilst the more expensive pegylated formulation requires one injection per cycle. The cost of G-CSF prophylaxis should be considered as part of the evaluation of the TAC regimen. Any additional sources of evidence? Are you aware of any relevant evidence which may not be found by a technology-focused systematic review of the available trial evidence? This could be information on recent and informal unpublished evidence or information from registries and other nationally coordinated clinical audits. Any such additional information must be accompanied by sufficient detail to enable a judgement to be made as to the quality of the evidence and to enable potential sources of bias to be determined. Recent trial results The BCIRG 006 study was presented at the at the San Antonio Breast Cancer Symposium in December This 3-arm study was restricted to women with HER2 +ve breast cancer. The control arm consisted of 4 cycles AC followed by 4 cycles of docetaxel. The 2 experimental arms both incorporated 12 months of adjuvant trastuzumab in combination with either the AC-docetaxel control arm, or a novel combination of carboplatin & docetaxel. Both experimental trastuzumab arms showed a highly significant reduction in the risk of recurrence apparently a smaller effect (but not statically significantly so) with carboplatin-docetaxel. Whilst this is a trial of trastuzumab and not docetaxel, the strongly positive results do emphasise the role of docetaxel & trastuzumab combination therapy in HER2 +ve breast cancer. The synergy between trastuzumab and cytotoxic drugs, particularly both docetaxel and paclitaxel has previously been demonstrated in metastatic breast cancer (Marty, J Clin Oncol : ; Slamon, New Engl J Med :783-92). Outstanding clinical trials ADEBAR: Study in higher risk patients comparing 4 cycles of epirubicin & cyclophosphamide followed by either 4 cycles of docetaxel or 4 cycles of a 28-day FEC regimen. Approximately 1200 patients were entered when the trial closed in September TACT: UK trial comparing either 8 cycles of FEC60 or E-CMF (centres were allowed to choose control arm) with 4 cycles of FEC60 followed by 4 cycles of docetaxel. Approximately 4200 patients were randomised. The initial analysis is expected in late DEVA: A randomised trial of sequential epirubicin and docetaxel (3 cycles each) versus epirubicin alone (6 cycles) in node-positive, postmenopausal breast cancer. Closed to recruitment in BCIRG 005: An ongoing randomised trial of AC (4 cycles) followed by docetaxel (4 cycles) compared to TAC (6 cycles) in 3,130 patients with node-positive early breast cancer. BIG 02-98: Ongoing trial comparing two regimens of doxorubicin, cyclophosphamide, methotrexate and fluorouracil, either with or without docetaxel, in women with node-positive, early breast cancer. 4
5 Implementation issues How would possible guidance have an impact on the delivery of care for patients with this condition? Would there be any need for NHS staff to be educated and trained? Would any additional resources be required (for example, facilities or equipment)? Under the Department of Health and Welsh Assembly Government, the NHS is required to provide funding and resources for medicines and treatments that have been recommended by NICE technology appraisals. This provision has to be made within 3 months from the date of publication of the guidance. If the technology is unlikely to be available in sufficient quantity or the staff and facilities to fulfil the general nature of the guidance can not be put in place within 3 months, NICE may advise the Department of Health and Welsh Assembly Government to vary this direction. Please note that NICE can not suggest variation in the direction on the basis of budgetary constraints alone. Implementation All oncologists treating breast cancer and the majority of chemotherapy daycare units are familiar with taxanes. Docetaxel is administered over 1 hour, which will will have no impact on the total chair time required to give adjuvant chemotherapy treatment. Docetaxel is unstable once diluted and the dose has to be within 6 hours of manufacture. This makes docetaxel unsuitable for batch manufacture and will place an additional burden on manufacturing units. The issue of febrile neutropenia and the need for prophylactic G-CSF support with the TAC regimen has been discussed above. Most patients can be trained to self administer G-CSF but its widespread adoption will require some community nursing resource, especially when the cheaper non-pegylated formulation is used. 5
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationAppendix D Clinical specialist statement template
Denosumab for the treatment of bone metastases from solid tumours Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationProfessional organisation statement template
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationTRANSPARENCY COMMITTEE OPINION. 15 February 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 February 2006 Taxotere 20 mg, concentrate and solvent for solution for infusion B/1 vial of Taxotere and 1 vial
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation Thank you for agreeing to give us a statement on your organisation s view of the technology and the way
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationIxekizumab for treating moderate to severe plaque psoriasis [ID904]
Thank you for agreeing to make a submission on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationThank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.
Appendix I - Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective
More informationAppendix D Clinical specialist statement template
Appendix D Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of pseudomonas lung infection in cystic fibrosis Thank you for agreeing to give us a statement on your organisation
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA) Ruxolitinib for the treatment of myelofibrosis
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationThank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationSubmission from xxxxxxxxxxxxxxxxxxxxxx/xxxxxxxxxxxxxxx of Let's Face It a Support Network for the facially disfigured.
From: xxxxxxxxxxxxxxxxxxxxxxx Sent: 12 September 2008 16:04 To: Jeremy Powell Subject: Re: NICE Appraisal: Head and neck cancer (squamous cell carcinoma) - cetuximab Single Technology Appraisal (STA) Appraisal
More informationBritish Geriatrics Society
Healthcare professional group/clinical specialist statement Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy
Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationOPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER. Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx
OPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx ANTHRACYCLINES AND TAXANES ARE COMMONLY USED USED IN MOST REGIMENS
More informationBreast Cancer Breast Managed Clinical Network
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive
More informationClinical Management Guideline for Breast Cancer
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Adjuvant Treatment Less than 4 positive lymph nodes ER Positive HER2 Negative (see page 2 & 3 ) Primary Diagnosis:
More informationSustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA
Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA The fascinating history of Herceptin 1981 1985 1987 1990 1992 1998 2000 2005 2006 2008 2011 Murine
More informationNadia Harbeck Breast Center University of Cologne, Germany
Evidence in Favor of Taxane Based Combinations and No Anthracycline in Adjuvant and Metastatic Settings Nadia Harbeck Breast Center University of Cologne, Germany Evidence in Favor of Taxane Based Combinations
More informationToxicities of Chemotherapy Regimens used in Early Breast Cancer
Toxicities of Chemotherapy Regimens used in Early Breast Cancer CERCIT Workshop February 17, 2012 Carlos H Barcenas, M.D., M.S. Fellow Hematology-Oncology MD Anderson Cancer Center CERCIT Scholar Outline
More informationAdjuvant Chemotherapy + Trastuzumab
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Chemotherapy + Trastuzumab (Optimal Drugs / Dosage / Trastuzumab) Adjuvant Chemotherapy (Optimal Drugs / Optimal Dosage
More informationAppendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2
Appendix 2 Adjuvant Regimens AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 CMF IV cyclophosphamide 600 mg/m 2 days 1 & 8 every 4 weeks methotrexate 40 mg/m 2 for 6 cycles
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationKey Words. Adjuvant therapy Breast cancer Taxanes Anthracyclines
The Oncologist Mayo Clinic Hematology/Oncology Reviews Adjuvant Therapy for Breast Cancer: Recommendations for Management Based on Consensus Review and Recent Clinical Trials BETTY A. MINCEY, a,b FRANCES
More information30 TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) NEW ADVANCES IN THE TREATMENT OF BREAST CANCER
EDUCATIONAL HIGHLIGHTS FROM DATA PRESENTED AT THE 30 TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) NEW ADVANCES IN THE TREATMENT OF BREAST CANCER DECEMBER 13 16, 2007, SAN ANTONIO, TX, USA 2 CONTENTS
More informationScottish Medicines Consortium
P Oral) Scottish Medicines Consortium vinorelbine 20 and 30mg capsules (NavelbineP Pierre Fabre Ltd No. (179/05) 06 May 2005 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationNational Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007
Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationNon-Anthracycline Adjuvant Therapy: When to Use?
Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationAdjuvant chemotherapy of breast cancer
Journal of BUON 10: 175-180, 2005 2005 Zerbinis Medical Publications. Printed in Greece REVIEW ARTICLE Adjuvant chemotherapy of breast cancer S. Bešlija Department of Medical Oncology, Institute of Oncology,
More informationTrastuzumab (Herceptin) for HER2 positive early, locally advanced and inflammatory breast cancer neoadjuvant treatment
Trastuzumab (Herceptin) for HER2 positive early, locally advanced and inflammatory breast cancer neoadjuvant treatment August 2010 This technology summary is based on information available at the time
More informationHorizon Scanning Centre November Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887
Horizon Scanning Centre November 2012 Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887 This briefing is based on information available at the time of research and a
More informationTreatment of HER-2 positive breast cancer
EJC SUPPLEMENTS 6 (2008) 21 25 available at www.sciencedirect.com journal homepage: www.ejconline.com Treatment of HER-2 positive breast cancer Matteo Clavarezza, Marco Venturini * Ospedale Sacro Cuore
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationBevacizumab added to a taxane for the first-line treatment of metastatic breast cancer
Appendix I Bevacizumab added to a taxane for the first-line treatment of metastatic breast cancer Primary Care Trusts (PCTs) provide a unique perspective on the technology, which is not typically available
More informationIdeal neo-adjuvant Chemotherapy in breast ca. Dr Khanyile Department of Medical Oncology, University of Pretoria
Ideal neo-adjuvant Chemotherapy in breast ca Dr Khanyile Department of Medical Oncology, University of Pretoria When is neo-adjuvant Chemo required? Locally advanced breast ca: - Breast conservative surgery
More informationPostoperative Adjuvant Chemotherapies. Stefan Aebi Luzerner Kantonsspital
Postoperative Adjuvant Chemotherapies Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Does Chemotherapy Work in Older Patients? ER : Chemotherapy vs nil Age
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Trastuzumab, as monotherapy and in combination with a taxane, for the treatment of metastatic breast cancer (to include
More informationHow to carry out health technology appraisals and guidance. Learning from the Scottish experience Richard Clark, Principal Pharmaceutical
The Managed Introduction of New Medicines How to carry out health technology appraisals and guidance. Learning from the Scottish experience Richard Clark, Principal Pharmaceutical Analyst July 10 th 2009,
More informationAuthor's response to reviews
Author's response to reviews Title: Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: A randomised study of sequential weekly versus
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationThank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationThe Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?
1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program
More informationHormonal therapies for the adjuvant treatment of early oestrogenreceptor-positive
Hormonal therapies for the adjuvant treatment of early oestrogenreceptor-positive breast cancer Issued: November 2006 guidance.nice.org.uk/ta112 NICE 2006 Contents 1 Guidance... 3 2 Clinical need and practice...
More informationEribulin for locally advanced or metastatic breast cancer third line; monotherapy
Eribulin for locally advanced or metastatic breast cancer third line; monotherapy April 2009 This technology summary is based on information available at the time of research and a limited literature search.
More informationExiste-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon
Existe-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon In 25 results of 4 Adjuvant Herceptin trials have definitively
More informationNeoadjuvant therapy a new pathway to registration?
Neoadjuvant therapy a new pathway to registration? Graham Ross, FFPM Clinical Science Leader Roche Products Ltd Welwyn Garden City, UK (full time employee) Themes Neoadjuvant therapy Pathological Complete
More informationUse of Taxanes in Older Breast Cancer Patients
SIOG Guidelines Update 2014: Use of Taxanes in Older Breast Cancer Patients Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Fundamental steps Task Force (TF) on
More informationBCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide and DOCEtaxel
BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin Cyclophosphamide DOCEtaxel Protocol Code Tumour Group Contact Physician BRAJFECD Breast Dr. Stephen Chia ELIGIBILITY:
More informationCOME HOME Innovative Oncology Business Solutions, Inc.
Innovative Oncology Business Solutions, Inc. Breast Cancer Diagnostic/Therapeutic Pathway V11, April 2015 Required Structured Data Fields: ICD9 Code Stage Staging Components Performance Status Treatment
More informationChapter. Contents Breast Cancer Adjuvant Epirubicin weekly. Docetaxel Copy No:
Chapter 2: Breast Cancer Contents Chapter 2: Breast Cancer... 1 Breast Cancer... 2 Adjuvant...... 2 Epi-CMF... 2 FEC / docetaxel... 3 FEC100... 4 AC/EC/TC... 4 (neo) adjuvant... 5... 5 HER2 positive: TCarboH...
More informationNovel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center
Novel Preoperative Therapies for HER2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center Key Findings to Date in the Neoadjuvant Therapy of HER2+
More informationEARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino
EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT
More informationLead team presentation Eribulin for treating locally advanced or metastatic breast cancer after two or more prior chemotherapy regimens STA
For projector and public [noacic] Lead team presentation Eribulin for treating locally advanced or metastatic breast cancer after two or more prior chemotherapy regimens STA 1 st Appraisal Committee meeting
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationCommon disease 175,000 new cases/year 44,000 deaths/year Less than 10% with newly diagnosed at presentation have stage IV disease Chronic disease,
Chemotherapy for Metastatic Breast Cancer: Recent Results HARMESH R. NAIK, MD. Karmanos Cancer Institute and St. Mary Hospital Metastatic breast cancer (MBC) Common disease 175,000 new cases/year 44,000
More informationSystemic Therapy for Locally Advanced Breast Cancer
Systemic Therapy for Locally Advanced Breast Cancer Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology National University Cancer Institute, Singapore Clinical Care Senior Principal
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More informationIncidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey
MEDICAL ONCOLOGY Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey S. Saibil MD PhD,* B. Fitzgerald
More information5-Fluorouracil, epirubicin 100 and Cyclophosphamide (FEC 100) Therapy
5-Fluorouracil, epirubicin 100 and Cyclophosphamide (FEC 100) Therapy INDICATIONS FOR USE: Regimen INDICATION ICD10 Code Neoadjuvant treatment for breast carcinoma C50 00265a Adjuvant treatment for breast
More informationCancer du sein métastatique et amélioration de la survie Pr. X. Pivot
Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Date of preparation: November 2015. EU0250i TTP/PFS Comparaisons First line metastatic breast cancer Monotherapy Docetaxel Chan 1999
More informationClinical Impact of primary prophylaxis for FN in breast cancer patients. Prof. Young Jin Suh The Catholic University of Korea
Clinical Impact of primary prophylaxis for FN in breast cancer patients Prof. Young Jin Suh The Catholic University of Korea Objectives Describe the prevalence of febrile neutropenia in patients with breast
More informationtrabectedin, 0.25 and 1mg powder for concentrate for solution for infusion (Yondelis ) SMC No. (452/08) Pharma Mar S.A. Sociedad Unipersonal
trabectedin, 0.25 and 1mg powder for concentrate for solution for infusion (Yondelis ) SMC No. (452/08) Pharma Mar S.A. Sociedad Unipersonal 08 October 2010 The Scottish Medicines Consortium (SMC) has
More informationTechnology appraisal guidance Published: 22 August 2012 nice.org.uk/guidance/ta263
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer Technology appraisal guidance Published: 22 August 2012 nice.org.uk/guidance/ta263 NICE 2018. All rights
More informationEarly and locally advanced breast cancer: diagnosis and management
National Institute for Health and Care Excellence Final Early and locally advanced breast cancer: diagnosis and management [E] Evidence reviews for adjuvant chemotherapy NICE guideline NG101 Evidence reviews
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Everolimus in combination with exemestane for the treatment of advanced or metastatic HER2 negative, oestrogen
More informationBreast cancer treatment
Report from the San Antonio Breast Cancer Symposium Breast cancer treatment Determining the best options for select patient groups Sara Soldera, MD, Resident; Nathaniel Bouganim, MD, FRCPC, Medical Oncologist;
More informationRelative dose intensity delivered to patients with early breast cancer: Canadian experience
M E D I C A L O N C O L O G Y Relative dose intensity delivered to patients with early breast cancer: Canadian experience S. Raza MD, S. Welch MD, and J. Younus MD ABSTRACT Adjuvant chemotherapy for early
More informationthat the best available evidence has not demonstrated that pcr can predict long-term outcomes in the neoadjuvant setting.
pcr in one arm of a randomized clinical trial comparing two neoadjuvant chemotherapies predicts for improved event-free or overall survival in that arm of the clinical trial. perc noted that the NeoALTTO
More informationpertuzumab 420mg concentrate for solution for infusion vial (Perjeta ) SMC No. (1121/16) Roche Products Limited
pertuzumab 420mg concentrate for solution for infusion vial (Perjeta ) SMC No. (1121/16) Roche Products Limited 05 February 2016 The Scottish Medicines Consortium (SMC) has completed its assessment of
More information亞東紀念醫院 Breast Cancer 化學治療處方集
亞東紀念醫院 Breast Cancer 化學治療處方集 2008-08 制定 最近修改日期 :2015-01 CMF Breast cancer 化學治療處方參考集 Adjuvant Classic CMF Cyclophosphamide 100mg/m2 PO qd; D1-D14 Methotrexate 40mg/m 2 in N/S 100 ml IV drip 30 mins; D1,
More informationNeoadjuvantTreatment In BC When, How, Who?
NeoadjuvantTreatment In BC When, How, Who? Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service, MSKCC Professor of Medicine, Weill Cornell Medical College President, ASCO 15 Potential Benefits Of
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
large impact on cost-effectiveness. perc discussed that one of the main factors affecting the costeffectiveness estimates was the survival estimates used in the economic model. In reviewing the clinical
More informationAdjuvant Chemotherapy TNBC & HER2 Subtype
Adjuvant Chemotherapy TNBC & HER2 Subtype 2015.08.15 Gun Min Kim Yonsei Cancer Center Division of Medical Oncology Department of Internal Medicine Yonsei University College of Medicine gmkim77@yuhs.ac
More informationReview Recent advances in systemic therapy Advances in adjuvant systemic chemotherapy of early breast cancer Sara López-Tarruella and Miguel Martín
Review Recent advances in systemic therapy Advances in adjuvant systemic chemotherapy of early breast cancer Sara López-Tarruella and Miguel Martín Medical Oncology Department, Clínico San Carlos Hospital,
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Cortazar P, Zhang L, Untch M, et al. Pathological
More information新竹馬偕紀念醫院癌症中心 乳癌化學治療藥物處方
新竹馬偕紀念醫院癌症中心 乳癌化學治療藥物處方 文件修訂記錄 修正次數 修正日期 修正版別 修 改 內 容 1 2011.04.07 1.0 初次訂定 2 2013.05.08 2.0 修訂 3 2013.04.30 3.0 修訂 :Triple-Negative Breast Cancer 處方 新增 :Neoadjuvant-p7~8 4 2014.04.29 4.0 修訂 :FEC + Trastuzumab
More informationNational Breast Cancer Audit next steps. Martin Lee
National Breast Cancer Audit next steps Martin Lee National Cancer Audits Current Bowel Cancer Head & Neck Cancer Lung cancer Oesophagogastric cancer New Prostate Cancer - undergoing procurement Breast
More informationClinical guideline Published: 23 February 2009 nice.org.uk/guidance/cg81
Advanced breast cancer: diagnosis and treatment Clinical guideline Published: 23 February 2009 nice.org.uk/guidance/cg81 NICE 20. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationHerceptin SC (Subcutaneous Trastuzumab)
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Rate 1 Herceptin SC (trastuzumab) 600mg S/C 2 to 5 mins *PRECAUTION: In order to reduce the risk of medication errors it is recommended that all trastuzumab
More informationPositive HER-2 tumor. How to incorporate the new drugs into neoadjuvance
Oncology Department Vall d Hebron University Hospital Barcelona. Spain Positive HER-2 tumor. How to incorporate the new drugs into neoadjuvance Javier Cortés June/2013 MD Anderson experience Buzdar et
More informationAdjuvant chemotherapy in older breast cancer patients: how to decide?
Adjuvant chemotherapy in older breast cancer patients: how to decide? H. Wildiers University Hospitals Leuven Belgium Wildiers H, Kunkler I, Lancet Oncol 2007 Biganzoli L, Wildiers H, Lancet Oncol. 2012
More informationGuideline for the Use of Granulocyte Colony Stimulating Factor (G-CSF) for Adults in Oncology and Haematology
(G-CSF) for Adults in Oncology and Haematology For Use in: By: Oncology and Haematology Inpatients and Outpatients Oncologists and Haematologists For: Division responsible for document: Key words: Name
More informationTechnology appraisal guidance Published: 7 March 2018 nice.org.uk/guidance/ta509
Pertuzumab with trastuzumab and docetaxel el for treating HER2-positive breast cancer Technology appraisal guidance Published: 7 March 20 nice.org.uk/guidance/ta509 NICE 20. All rights reserved. Subject
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 November 2006 TAXOTERE 20 mg, concentrate and solvent for infusion in single-dose vials of 7 ml, individually packed
More informationChemotherapy of Breast Cancer
Japan - Taiwan Joint Symposium on Medical Oncology Session 7 Breast cancer journal homepage:www.cos.org.tw/web/index.asp Chemotherapy of Breast Cancer Mei-Ching Liu Department of Medicine, Koo Foundation
More informationThe Three Ages of Systemic Adjuvant Therapy for EBC
The Three Ages of Systemic Adjuvant Therapy for EBC 1896-2018 Nicholas Wilcken Westmead Hospital Petersham Institute University of Sydney Questions to be answered (concentrating on chemotherapy) Why should
More informationCASE STUDIES CLINICAL CASE SCENARIOS. Matthew J. Ellis, MD, PhD
CLINICAL CASE SCENARIOS Matthew J. Ellis, MD, PhD Clinicians face daily challenges in the management of individual patients with breast cancer who demonstrate different characteristics in terms of estrogen
More informationSan Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
More informationDR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA
Recent Advances of Docetaxel in Management of Breast Cancer DR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA 1 ADJUVANT
More informationBreast cancer remains the most common malignancy and the second leading. cause of cancer mortality in women in the United States.
Dr. Andrew Seidman s Commentary I. Breast Cancer Overview Breast cancer remains the most common malignancy and the second leading cause of cancer mortality in women in the United States. The following
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More information